184 related articles for article (PubMed ID: 23305654)
1. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.
Uria-Nickelsen M; Neckermann G; Sriram S; Andrews B; Manchester JI; Carcanague D; Stokes S; Hull KG
Int J Antimicrob Agents; 2013 Apr; 41(4):363-71. PubMed ID: 23305654
[TBL] [Abstract][Full Text] [Related]
2. Novel DNA gyrase inhibitors: microbiological characterisation of pyrrolamides.
Uria-Nickelsen M; Blodgett A; Kamp H; Eakin A; Sherer B; Green O
Int J Antimicrob Agents; 2013 Jan; 41(1):28-35. PubMed ID: 23142086
[TBL] [Abstract][Full Text] [Related]
3. Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
Hossion AM; Zamami Y; Kandahary RK; Tsuchiya T; Ogawa W; Iwado A; Sasaki K
J Med Chem; 2011 Jun; 54(11):3686-703. PubMed ID: 21534606
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
Huband MD; Cohen MA; Zurack M; Hanna DL; Skerlos LA; Sulavik MC; Gibson GW; Gage JW; Ellsworth E; Stier MA; Gracheck SJ
Antimicrob Agents Chemother; 2007 Apr; 51(4):1191-201. PubMed ID: 17261623
[TBL] [Abstract][Full Text] [Related]
6. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
[TBL] [Abstract][Full Text] [Related]
8. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
[TBL] [Abstract][Full Text] [Related]
9. Activity of a novel series of acylides active against community-acquired respiratory pathogens.
Pandya M; Chakrabarti A; Rathy S; Katoch R; Venkataraman R; Bhateja P; Mathur T; Kumar GR; Malhotra S; Rao M; Bhadauria T; Barman TK; Das B; Upadhyay D; Bhatnagar PK
Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666
[TBL] [Abstract][Full Text] [Related]
10. Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
Ho SY; Wang W; Ng FM; Wong YX; Poh ZY; Tan SWE; Ang SH; Liew SS; Joyner Wong YS; Tan Y; Poulsen A; Pendharkar V; Sangthongpitag K; Manchester J; Basarab G; Hill J; Keller TH; Cherian J
Eur J Med Chem; 2018 Sep; 157():610-621. PubMed ID: 30125722
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
12. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
[TBL] [Abstract][Full Text] [Related]
13. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
[TBL] [Abstract][Full Text] [Related]
14. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
[TBL] [Abstract][Full Text] [Related]
16. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects.
Ibrahim NM; Fahim SH; Hassan M; Farag AE; Georgey HH
Eur J Med Chem; 2022 Jan; 228():114021. PubMed ID: 34871841
[TBL] [Abstract][Full Text] [Related]
18. High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance.
Jeverica S; Golparian D; Hanzelka B; Fowlie AJ; Matičič M; Unemo M
J Antimicrob Chemother; 2014 Jul; 69(7):1866-72. PubMed ID: 24651828
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
Tanitame A; Oyamada Y; Ofuji K; Fujimoto M; Iwai N; Hiyama Y; Suzuki K; Ito H; Terauchi H; Kawasaki M; Nagai K; Wachi M; Yamagishi J
J Med Chem; 2004 Jul; 47(14):3693-6. PubMed ID: 15214796
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
